International Journal of Clinical Research

Objective: To analyze the clinical effect of cytarabine consolidation therapy in newly treated patients with acute myeloid leukemia. Methods: In this paper, 60 cases of newly treated acute myeloid leukemia patients received by our hospital were screened, and all included cases were randomly selected into two groups for control study. The group was mainly divided into observation group and control group, with 30 patients in each group, and both groups were treated with daunorubicin. Meanwhile, the control group was given a medium dose of cytarabine consolidation treatment, while the observation group was given a standard dose of cytarabine consolidation treatment. Finally, the therapeutic effects of the two groups were compared. Results: after treatment, according to the results of two groups of the indicators for the total effective rate of observation group patients increased significantly compared with control group, the patients immune index, insulin-like growth factor and leukemia inhibitory factor level improved significantly compared with control group, the incidence of drug adverse reaction in patients with significantly lower than the control group (P < 0.05). Conclusion: Adding cytarabine in the treatment of acute myeloid leukemia patients for consolidation therapy can effectively improve the clinical treatment effect, so that the clinical indicators of patients can be well improved, and the safety of medication is high, so it can improve the disease control effect of patients, reduce the harm of the disease.

Acute Myeloid Leukemia; Cytarabine; Consolidation Therapy; Effect Analysis